Reviewed by WANGYATAO·Last reviewed 2026-11-11·Medical disclaimer

In short

China's 2025 clinical specification for antibiotic use tightens stewardship: it defines indication boundaries, promotes culture-guided and de-escalation therapy, restricts reserved (special-use) agents, and reinforces duration limits to curb resistance.

What this guide covers: Why stewardship matters · Indication and selection · Culture-guided and de-escalation · Reserved and special-use agents · For patients

Why stewardship matters

Antimicrobial resistance is a major public-health threat. China's 2025 specification standardizes how clinicians choose, dose, and stop antibiotics to preserve effectiveness and reduce adverse events.

Indication and selection

Antibiotics should be used only for confirmed or strongly suspected bacterial infection, with the narrowest-spectrum agent that covers the likely pathogen. Empiric therapy is guided by site, severity, local resistance patterns, and patient factors.

Culture-guided and de-escalation

Whenever possible, cultures are obtained before starting therapy. Once pathogens and sensitivities are known, treatment is de-escalated to a targeted regimen rather than kept broad.

Reserved and special-use agents

Certain broad-spectrum and carbapenem-class drugs are restricted to specialists or MDT approval to prevent overuse. Duration is kept as short as evidence allows (often 5–7 days for many infections).

For patients

Do not request antibiotics for viral illnesses such as colds. Complete the prescribed course as directed, and ask whether a shorter, targeted course is appropriate for your infection.

Sources and further reading

One reference to a U.S. government health source (National Institutes of Health or MedlinePlus) for the medical background of this guide. It is context, not a substitute for advice from your treating doctor.

General information for international patients, not medical advice or a diagnosis. Read the medical disclaimer.